Financials
Financial year 2025
Worth noting
- More debts than assets in the latest financial year.
- A loss two years in a row.
- The team shrank two years in a row.
- Figures corrected afterwards (2021, 2022).
Gross margin
€ 2.1 million
▲ 72% vs 2024
Profit
Caution€ -3.8 million
▲ 26% vs 2024
Debts
High€ 5.5 million
▼ 47% vs 2024
OncoDNA from Charleroi, company number BE0501631837, closed financial year 2025 with a result of € -3.8 million after tax. For that financial year OncoDNA recorded a gross margin of € 2.1 million and equity of € -256,642. Compared with financial year 2024, the result moved from € -5.1 million to € -3.8 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.
What happened at OncoDNA?
What happened at OncoDNA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 3.8 million. Source: NBB ↗
- Geldhof Entreprises SPRL stepped down as director. NBB
- Société Fédérale de Participations et d'Investissement (S.F.P.I.) stepped down as director. NBB
- Charles-André Brouwers stepped down as director. NBB
- François Blondel stepped down as director. NBB
- An Herremans stepped down as director. NBB
- Geldhof Entreprises SPRL became a director. NBB
- Société Fédérale de Participations et d'Investissement (S.F.P.I.) became a director. NBB
In short
From € 5.3 million loss in 2021 to € 3.8 million loss in 2025.
Paid € 22,546 in corporate taxes since 2021.
On average € 101,000 of value added per employee in 2025.
A new publication or filing at OncoDNA? We notify you, reason included.
Follow OncoDNANeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of Biosequences SLU and 66.1% of Integragen itself.
Directors
According to the 2025 annual accounts
Director · represented by Guy Geldhof
since 2023 · until 2026
Société Fédérale de Participations et d'Investissement (S.F.P.I.)
Director · represented by François Fontaine
Also active at: Aviapartner Belgium, Société Anonyme Belge de Constructions Aéronautiques, Société Nationale de Construction Aérospatiale +62 more
since 2023 · until 2026
Charles-André Brouwers
Director
since 2023 · until 2026
since 2023 · until 2026
An Herremans
Director
Also active at: AANNEMINGSMAATSCHAPPIJ CFE, V.M.A., AGIDENS INTERNATIONAL +5 more
since 2023 · until 2026
Establishments
Establishment units
Physical locations of this company
Rue Louis Breguet 1
6041 Charleroi
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Microsoft 365
Hosting
PLANETHOSTER-8 - PlanetHoster, CA
DNS
Google Cloud DNS
Domain
Domain
oncodna.com
Registered
2012-08-03
Registrar
Gandi SAS
Expires
2026-08-03
Website info
Features
Security
Details
- Company number
- 0501.631.837
- VAT number
- BE 0501.631.837
- Registered office
- Rue Louis Breguet 1, 6041 Charleroi
- Names & denominations
- OncoDNA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 November 2012
- Peppol
- Active · Active since 20 Nov 2025
- Contact
- oncodna.com corporate@oncodna.com
- Activities · NACE
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria